Doença enxerto contra o hospedeiro cutânea aguda: incidência e impacto na mortalidade
Data
2016-09-02
Autores
Serignolli, Ana Letícia [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
A Doença Enxerto Contra o Hospedeiro (DECH) é uma das principais complicações em pacientes pós transplante de células tronco hematopoiéticas (TCTH), onde as células T do doador agridem os tecidos do receptor resultando em uma das principais causas de mortalidade e morbidade. Ocorre em cerca de metade dos pacientes que realizaram transplante de células tronco hematopoiéticas (TCTH). A pele é um dos órgãos mais acometidos. A DECH é dividida da forma aguda (DECH-a) e crônica (DECH-c), de acordo com o tempo de aparecimento dos achados clínicos e histopatológicos. A DECH de pele é classificada em graus variados, de I a IV, de acordo com o comprometimento. O presente estudo teve como objetivo avaliar a incidência de DECH-a cutânea entre os pacientes submetidos ao TCTH alogênico, aparentado, no Serviço de Transplante de Medula Óssea do Hospital Amaral Carvalho em Jaú/SP. Também foi objetivo do estudo a análise do perfil destes pacientes, a incidência e o impacto da doença na mortalidade precoce nos 100 primeiros dias pós TCTH. Os procedimentos metodológicos envolveram análise retrospectiva de dados retirados de planilhas do setor administrativo do Serviço de Transplante de Medula Óssea do Hospital Amaral Carvalho em Jaú/SP, contendo informações de 1113 pacientes que estiveram internados para a realização de transplante de medula óssea alogênico, aparentado, no período de agosto de 1996 a dezembro de 2013. Foram incluídos 582 pacientes cujas as doenças eram de linhagem mielóide - as mielopatias malignas (Leucemia Mieloide Aguda, Leucemia Mieloide Crônica, Síndrome Mielodisplásica e Doença Mieloproliferativa Crônica) para que o grupo pesquisado se tornasse homogêneo em termos de drogas e condicionamento. Esses 582 pacientes englobaram 2 grupos: pacientes que apresentaram DECH-a exclusiva de pele e pacientes que não apresentaram nenhum tipo de DECH. Todos os dados foram revisados e submetidos a análise estatística univariada e multivariada. Na análise univariada, observa-se maior sobrevida em 10 anos para os indivíduos com DECH-a de pele grau I e II (p=0.039) e para os transplantados com células de Medula Óssea (0.018). Essa significância estatística foi mantida na análise multivariada. A principal causa da mortalidade nos primeiros 100 primeiros dias do transplante foi a recidiva da doença de base, sendo a DECH aguda responsável por 6% dos óbitos nesse período. Não houve diferença significativa para os outros dados pesquisados. Conclui-se então que uma escolha adequada de doadores, além do uso de fonte de medula óssea como principal escolha para realização de transplante de medula óssea, podem diminuir a incidência de DECH-a de pele, além de aumentar a sobrevida dos pacientes transplantados.
Graft versus host disease (GVHD) is a major complication occurred in patients posttransplantation hematopoietic stem cell transplantation (HSCT), where the donor's T cells attack the recipient's tissues resulting in a major cause of mortality and morbidity.This is a recurrent and severe event, which occurs in about half of patients who underwent hematopoietic stem cell transplantation (HSCT), the skin is one of the most affected organs. GVHD is divided as acute (GVHD) and chronic (chronic GVHD), according to the time, clinical and histopathological findings. This study aimed to evaluate the incidence of GVHDskin among patients undergoing allogeneic HSCT, akin in Marrow Transplant Service Bone Amaral Carvalho Hospital, Jaú / SP, the profile of this patient and the impact of the disease in early mortality in the first 100 days after HSCT. The methodological procedures involved retrospective analysis of data from spreadsheets in the administrative sector of the Bone Marrow Transplant Service, Hospital Amaral Carvalho - Jau, containing information of 1,113 patients who were hospitalized for performing allogeneic bone marrow transplantation, related in the period August 1996 to December 2013. to equalize the analysis were included only 582 patients whose diseases were of myeloid lineage - malignant myelopathy (Acute myeloid Leukemia, Chronic myeloid Leukemia, Myelodysplastic Syndrome and Chronic myeloproliferative disease) so that the study group became homogeneous in terms of drugs and conditioning. These 582 patients were divided into 2 groups: patients with GVHDexclusive skin and patients without any GVHD. All data were reviewed and subjected to statistical analysis. In univariate analysis, there is greater survival at 10 years for patients with GVHD to skin grade I and II (p = 0.039) and the transplanted cells Bone Marrow (0018). This significance was maintained in multivariate analysis. The main cause of mortality in the first 100 early days of transplantation was the recurrence of the underlying disease, and acute GVHD responsible for 6% of deaths in this period. There was no significant difference for the other surveyed data. It was concluded that a suitable choice of donors, and the use of bone marrow source as the primary choice for bone marrow transplantation, can reduce the incidence of GVHD, the skin, and increase the survival rate of transplant patients.
Graft versus host disease (GVHD) is a major complication occurred in patients posttransplantation hematopoietic stem cell transplantation (HSCT), where the donor's T cells attack the recipient's tissues resulting in a major cause of mortality and morbidity.This is a recurrent and severe event, which occurs in about half of patients who underwent hematopoietic stem cell transplantation (HSCT), the skin is one of the most affected organs. GVHD is divided as acute (GVHD) and chronic (chronic GVHD), according to the time, clinical and histopathological findings. This study aimed to evaluate the incidence of GVHDskin among patients undergoing allogeneic HSCT, akin in Marrow Transplant Service Bone Amaral Carvalho Hospital, Jaú / SP, the profile of this patient and the impact of the disease in early mortality in the first 100 days after HSCT. The methodological procedures involved retrospective analysis of data from spreadsheets in the administrative sector of the Bone Marrow Transplant Service, Hospital Amaral Carvalho - Jau, containing information of 1,113 patients who were hospitalized for performing allogeneic bone marrow transplantation, related in the period August 1996 to December 2013. to equalize the analysis were included only 582 patients whose diseases were of myeloid lineage - malignant myelopathy (Acute myeloid Leukemia, Chronic myeloid Leukemia, Myelodysplastic Syndrome and Chronic myeloproliferative disease) so that the study group became homogeneous in terms of drugs and conditioning. These 582 patients were divided into 2 groups: patients with GVHDexclusive skin and patients without any GVHD. All data were reviewed and subjected to statistical analysis. In univariate analysis, there is greater survival at 10 years for patients with GVHD to skin grade I and II (p = 0.039) and the transplanted cells Bone Marrow (0018). This significance was maintained in multivariate analysis. The main cause of mortality in the first 100 early days of transplantation was the recurrence of the underlying disease, and acute GVHD responsible for 6% of deaths in this period. There was no significant difference for the other surveyed data. It was concluded that a suitable choice of donors, and the use of bone marrow source as the primary choice for bone marrow transplantation, can reduce the incidence of GVHD, the skin, and increase the survival rate of transplant patients.
Descrição
Palavras-chave
Transplante de Medula Óssea, Doença do Enxerto Contra o Hospedeiro, Sobrevida, Bone marrow transplantation, Graft-versus-host disease, Survival